Trial update: the Diabetes REduction Approaches with ramipril and rosiglitazone Medications (DREAM) trial
BACKGROUND Diabetes (T2DM) is a worldwide medical and social emergency in the westernized societies. Lifestyle changes, diet and physical activity, have shown a protective effect on the likelihood of developing T2DM and are strongly recommended for primary prevention in people at increased risk for...
Main Author: | G. Gulli |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2013-05-01
|
Series: | Italian Journal of Medicine |
Subjects: | |
Online Access: | http://www.italjmed.org/index.php/ijm/article/view/378 |
Similar Items
-
Ramipril - angiotensin converting enzyme ingibitor with a wide spectrum of therapeutic action
by: Dmitriy Vladimirovich Preobrazhenskiy,, et al.
Published: (2009-03-01) -
Association Between Diabetes Medications and the Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis
by: Xiaocui Qin, et al.
Published: (2021-07-01) -
Tolerability of Ramipril 10 mg Daily in High-risk Cardiovascular Patients in Taiwan: Experience from Kaohsiung Medical University Chung-Ho Memorial Hospital
by: Chih-Sheng Chu, et al.
Published: (2005-11-01) -
Correlation of renin angiotensin system (RAS) candidate gene polymorphisms with response to Ramipril in patients with essential hypertension
by: S Gupta, et al.
Published: (2015-01-01) -
Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC
by: Vincenza Ciaramella, et al.
Published: (2019-04-01)